Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.

Permar, Sallie R

Fong, Youyi

Vandergrift, Nathan

Fouda, Genevieve G

Gilbert, Peter

Parks, Robert

Jaeger, Frederick H

Pollara, Justin

Martelli, Amanda

Liebl, Brooke E

Lloyd, Krissey

Yates, Nicole L

Overman, R Glenn

Shen, Xiaoying

Whitaker, Kaylan

Chen, Haiyan

Pritchett, Jamie

Solomon, Erika

Friberg, Emma

Marshall, Dawn J

Whitesides, John F

Gurley, Thaddeus C

Von Holle, Tarra

Martinez, David R

Cai, Fangping

Kumar, Amit

Xia, Shi-Mao

Lu, Xiaozhi

Louzao, Raul

Wilkes, Samantha

Datta, Saheli

Sarzotti-Kelsoe, Marcella

Liao, Hua-Xin

Ferrari, Guido

Alam, S Munir

Montefiori, David C

Denny, Thomas N

Moody, M Anthony

Tomaras, Georgia D

Gao, Feng

Haynes, Barton F

United States

2016-06-01T14:02:18Z

2015-07-01

Despite the wide availability of antiretroviral drugs, more than 250,000 infants are vertically infected with HIV-1 annually, emphasizing the need for additional interventions to eliminate pediatric HIV-1 infections. Here, we aimed to define humoral immune correlates of risk of mother-to-child transmission (MTCT) of HIV-1, including responses associated with protection in the RV144 vaccine trial. Eighty-three untreated, HIV-1-transmitting mothers and 165 propensity score-matched nontransmitting mothers were selected from the Women and Infants Transmission Study (WITS) of US nonbreastfeeding, HIV-1-infected mothers. In a multivariable logistic regression model, the magnitude of the maternal IgG responses specific for the third variable loop (V3) of the HIV-1 envelope was predictive of a reduced risk of MTCT. Neutralizing Ab responses against easy-to-neutralize (tier 1) HIV-1 strains also predicted a reduced risk of peripartum transmission in secondary analyses. Moreover, recombinant maternal V3-specific IgG mAbs mediated neutralization of autologous HIV-1 isolates. Thus, common V3-specific Ab responses in maternal plasma predicted a reduced risk of MTCT and mediated autologous virus neutralization, suggesting that boosting these maternal Ab responses may further reduce HIV-1 MTCT.

http://www.ncbi.nlm.nih.gov/pubmed/26053661

81593

1558-8238

https://hdl.handle.net/10161/12060

eng

American Society for Clinical Investigation

J Clin Invest

10.1172/JCI81593

AIDS Vaccines

Antibodies, Neutralizing

Antibody Specificity

Antigens, Viral

Cohort Studies

Female

HIV Antibodies

HIV Envelope Protein gp120

HIV Infections

HIV-1

Humans

Immunoglobulin G

Infant

Infant, Newborn

Infectious Disease Transmission, Vertical

Logistic Models

Multivariate Analysis

Peptide Fragments

Pregnancy

Pregnancy Complications, Infectious

Risk Factors

Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.

Journal article

Ferrari, Guido|0000-0001-7747-3349

Alam, S Munir|0000-0003-0941-0703

Montefiori, David C|0000-0003-0856-6319

Moody, M Anthony|0000-0002-3890-5855

Tomaras, Georgia D|0000-0001-8076-1931

Gao, Feng|0000-0001-8903-0203

http://www.ncbi.nlm.nih.gov/pubmed/26053661

2702

2706

7

Basic Science Departments

Clinical Science Departments

Duke

Duke Cancer Institute

Duke Human Vaccine Institute

Global Health Institute

Immunology

Institutes and Centers

Institutes and Provost's Academic Units

Medicine

Medicine, Duke Human Vaccine Institute

Medicine, Infectious Diseases

Molecular Genetics and Microbiology

Pathology

Pediatrics

Pediatrics, Infectious Diseases

School of Medicine

Staff

Surgery

Surgery, Surgical Sciences

Surgery, Surgical Sciences Section for AIDS Research & Development

University Institutes and Centers

Published

125